Acadia Pharmaceuticals announced that their medication Nuplazid did not show improvement in the social and emotional symptoms of schizophrenia in a Phase 3 clinical trial. This is a setback for the company’s plans to expand the use of Nuplazid for schizophrenia treatment, as it is currently only approved for Parkinson’s disease psychosis. Acadia’s CEO expressed disappointment at the trial results, citing the need for better treatment options for patients with negative symptoms of schizophrenia. This news highlights the challenges in developing effective medications for mental health disorders.
Source link
Acadia’s Nuplazid fails as schizophrenia medicine in Phase 3 study
